Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Haemonetics's annualized net income for the quarter that ended in Mar. 2026 was €-70 Mil. Haemonetics's average shareholder tangible equity for the quarter that ended in Mar. 2026 was €-182 Mil. Therefore, Haemonetics's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was N/A%.
The historical rank and industry rank for Haemonetics's Return-on-Tangible-Equity or its related term are showing as below:
STU:HAZ'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -8.75 Med: 26.72 Max: 482.13
Current: Negative Tangible Equity
During the past 13 years, Haemonetics's highest Return-on-Tangible-Equity was 482.13%. The lowest was -8.75%. And the median was 26.72%.
STU:HAZ's Return-on-Tangible-Equity is ranked better than 99.87% of 759
companies
in the Medical Devices & Instruments industry
Industry Median: 4.04
vs STU:HAZ: Negative Tangible Equity
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Haemonetics Return-on-Tangible-Equity Related Terms
Haemonetics Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Haemonetics's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:HAZ vs ITGR, IRTC, ESTA: Return-on-Tangible-Equity Comparison
For the Medical Devices subindustry, Haemonetics's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Haemonetics Return-on-Tangible-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Haemonetics's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Haemonetics's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 0.00% mean?
Haemonetics (STU:HAZ) has a Return-on-Tangible-Equity of 0.00% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Haemonetics and its competitors. According to the industry distribution chart, Haemonetics ranks #1 out of 759 companies in the Medical Devices & Instruments industry, placing it in the top 0.099999999999994%.
Is Haemonetics' Return-on-Tangible-Equity too high?
Haemonetics' current Return-on-Tangible-Equity is 0.00%. Based on the distribution chart, Haemonetics ranks #1 out of 759 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Haemonetics has a GF Score™ of 87/100, reflecting its overall financial health beyond just this single metric.
How does Haemonetics' Return-on-Tangible-Equity compare to ITGR and IRTC?
According to the Medical Devices & Instruments industry distribution chart, Haemonetics ranks #1 out of 759 companies for Return-on-Tangible-Equity. This places Haemonetics in the top 0% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Equity is 4.04. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Devices & Instruments company?
The median Return-on-Tangible-Equity among Medical Devices & Instruments companies is 4.04, based on 759 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Haemonetics and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Equity is 4.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Haemonetics's current Return-on-Tangible-Equity is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Haemonetics stock overvalued right now?
Haemonetics (STU:HAZ) has a current Return-on-Tangible-Equity of 0.00%. The stock's GF Value™ is €73.85, compared to a current price of €64.50 — trading 12.7% below its estimated fair value. The current Return-on-Tangible-Equity is 0.00%. Haemonetics' overall GF Score™ is 87/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Haemonetics (STU:HAZ), the current Return-on-Tangible-Equity is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Haemonetics (STU:HAZ) Overvalued in 2026?
Based on GuruFocus' analysis, Haemonetics stock appears to be undervalued.
The current stock price of €64.50 is trading 12.7% below its estimated GF Value™ of €73.85.
Key valuation signals for STU:HAZ:
Return-on-Tangible-Equity: 0.00%
GF Value™: €73.85 vs. price of €64.50 (12.7% below fair value)
No single metric tells the full story. See the STU:HAZ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.
87GF Score
Get the complete analysis for STU:HAZ
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:HAZ has been successfully added to your 
